Targeting apoptosis in prostate cancer.

[1]  J. Melo,et al.  Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[2]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[3]  G. F. Sullivan,et al.  Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. , 2000, The Journal of clinical investigation.

[4]  E. Alnemri,et al.  Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. , 2000, Cancer research.

[5]  Matthew G. Vander Heiden,et al.  Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis? , 1999, Nature Cell Biology.

[6]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[7]  J C Reed,et al.  Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases , 1999, The EMBO journal.

[8]  L. Pfeffer,et al.  NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase , 1999, Nature.

[9]  R. DiPaola,et al.  Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Lutz,et al.  Bak BH3 Peptides Antagonize Bcl-xL Function and Induce Apoptosis through Cytochrome c-independent Activation of Caspases* , 1999, The Journal of Biological Chemistry.

[11]  S. Cannistra,et al.  In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. , 1999, Cancer research.

[12]  W. Zong,et al.  The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis , 1999 .

[13]  J C Reed,et al.  IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.

[14]  S. Korsmeyer.  BCL-2 gene family and the regulation of programmed cell death. , 1995, Cancer research.

[15]  C. Sawyers,et al.  The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[17]  G. F. Sullivan,et al.  The expression of drug resistance gene products during the progression of human prostate cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  R. Vessella,et al.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Larson,et al.  Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  H. Pehamberger,et al.  bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice , 1998, Nature Medicine.

[21]  G. Mills,et al.  MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. , 1997, Cancer research.

[22]  J. Herman,et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.

[23]  R. DiPaola,et al.  Effect of 13-cis-retinoic acid and α-interferon on transforming growth factor in patients with rising prostate-specific antigen , 1997 .

[24]  John Calvin Reed.  Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. , 1997, Seminars in hematology.

[25]  Guy S. Salvesen,et al.  X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.

[26]  E. Solary,et al.  Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. , 1997, Journal of the National Cancer Institute.

[27]  E. Borden,et al.  Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  D. Cunningham,et al.  BCL-2 antisense therapy in patients with non-Hodgkin lymphoma , 1997, The Lancet.

[29]  S. Korsmeyer,et al.  bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[31]  M. Loda,et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.

[32]  G. Miller,et al.  Comparison of ras activation in prostate carcinoma in Japanese and American men , 1997, The Prostate.

[33]  P. Wingo,et al.  Cancer statistics, 1997 , 1997, CA: a cancer journal for clinicians.

[34]  D. McConkey,et al.  Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. , 1996, Cancer research.

[35]  Marc W. Kirschner,et al.  How Proteolysis Drives the Cell Cycle , 1996, Science.

[36]  E. White,et al.  Lamin proteolysis facilitates nuclear events during apoptosis , 1996, The Journal of cell biology.

[37]  M. Minden,et al.  Regulation of the synthesis of bcl-2 protein by growth factors. , 1996, Leukemia.

[38]  A. Levine,et al.  Wild-type p53 negatively regulates the expression of a microtubule-associated protein. , 1996, Genes & development.

[39]  David Baltimore,et al.  NF-κB: Ten Years After , 1996, Cell.

[40]  T. Aas,et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.

[41]  John Calvin Reed,et al.  Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. , 1996, The American journal of pathology.

[42]  M. Vidal,et al.  Dominant-negative p53 mutations selected in yeast hit cancer hot spots. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  L. Neckers,et al.  Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. , 1996, Cancer research.

[44]  C. Croce,et al.  Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. , 1996, Cancer research.

[45]  G. Demers,et al.  Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. , 1996, Cancer research.

[46]  G. Demers,et al.  Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis , 1996, Nature Medicine.

[47]  M. Reiss,et al.  Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer , 1996, Cancer Chemotherapy and Pharmacology.

[48]  H. Perlman,et al.  Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. , 1995, Cancer research.

[49]  M. Campbell,et al.  Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. , 1995, Cancer letters.

[50]  C. Croce,et al.  Inactivation of Bcl-2 by phosphorylation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[51]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[52]  C. Der,et al.  ras Proto-Oncogene Activation in Human Malignancy , 1995 .

[53]  W. Kreis.  Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer. , 1995, Cancer investigation.

[54]  R. Vessella,et al.  Inhibition of tumorigenic potential and prostate‐specific antigen expression in LNCaP human prostate cancer cell line by 13‐cis‐retinoic acid , 1994, International journal of cancer.

[55]  S. Jabłońska,et al.  Synergistic effect of retinoids and interferon α on tumor‐induced angiogenesis: Anti‐angiogenic effect on HPV‐harboring tumor‐cell lines , 1994, International journal of cancer.

[56]  E. White,et al.  Bcl-2 blocks p53-dependent apoptosis , 1994, Molecular and cellular biology.

[57]  M. Birnbaum,et al.  An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs , 1994, Journal of virology.

[58]  Mark S. Boguski,et al.  Proteins regulating Ras and its relatives , 1993, Nature.

[59]  M. Scheffner,et al.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.

[60]  W. W. Nichols,et al.  p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. , 1993, Journal of the National Cancer Institute.

[61]  B. Yeap,et al.  Taxol in advanced, hormone‐refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology group , 1993, Cancer.

[62]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[63]  D. Chopin,et al.  Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. , 1993, The American journal of pathology.

[64]  M. Scheffner,et al.  Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins , 1993, Molecular and cellular biology.

[65]  S. Hilsenbeck,et al.  p53 is mutated in a subset of advanced-stage prostate cancers. , 1993, Cancer research.

[66]  E. White,et al.  Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. , 1993, Genes & development.

[67]  M. Campbell,et al.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.

[68]  J. Buckner,et al.  A phase II study of recombinant human alpha‐interferon in advanced hormone‐refractory prostate cancer , 1992, Cancer.

[69]  K. Kinzler,et al.  Oncogenic forms of p53 inhibit p53-regulated gene expression , 1992 .

[70]  B. Cheson,et al.  Retinoids in cancer therapy. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  S. Lippman,et al.  13-cis-Retinoic Acid Plus Interferon α -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix , 1992 .

[72]  R. Weber,et al.  13-cis-Retinoic Acid and Interferon α -2a: Effective Combination. Therapy for Advanced Squamous Cell Carcinoma of the Skin , 1992 .

[73]  F. McCormick,et al.  Interactions between p21ras proteins and their GTPase activating proteins. , 1992, Cancer surveys.

[74]  W. Isaacs,et al.  Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. , 1991, Cancer research.

[75]  W. Isaacs,et al.  ras gene mutations in human prostate cancer. , 1990, Cancer research.

[76]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[77]  G. Murphy,et al.  Interferon‐β treatment of metastatic prostate cancer , 1986 .

[78]  Y. Tsujimoto,et al.  Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[79]  H. Mogami,et al.  Effects of bromocriptine on prolactin‐secreting pituitary adenomas. Mechanism of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis , 1985, Cancer.

[80]  C. Vogel,et al.  Phase I study and pharmacokinetics of weekly high-dose 13-cis-retinoic acid. , 1985, Cancer research.

[81]  M. Wigler,et al.  Three human transforming genes are related to the viral ras oncogenes. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[82]  M. Lippman,et al.  Pharmacology of 13-cis-retinoic acid in humans. , 1982, Cancer research.